Reexploring the STRESS Trial: Subgroup Postoperative Outcomes Following Methylprednisolone for Infant Heart Surgery.

Area of Science:

• Pediatric Cardiac Surgery
• Pharmacology
• Critical Care Medicine

Background:

• Infant heart surgery carries significant risks, including mortality and complications.
• The use of corticosteroids like methylprednisolone aims to reduce systemic inflammation post-surgery.
• Optimal steroid use in this vulnerable population remains under investigation.

Purpose of the Study:

• To assess the association between intraoperative methylprednisolone and specific postoperative outcomes in infants undergoing heart surgery.
• To analyze these outcomes across various patient subgroups.

Main Methods:

• Subpopulation analyses from a double-blind, randomized, placebo-controlled trial (The Steroids to Reduce Systemic Inflammation after Infant Heart Surgery trial).
• Infants under 1 year old undergoing heart surgery with cardiopulmonary bypass were stratified by STAT Mortality Category, age, gestational age, and presence of chromosomal or syndromic diagnosis (CSD).
• Methylprednisolone was administered via cardiopulmonary bypass pump-priming fluid versus placebo.

Main Results:

• Methylprednisolone did not reduce the odds of death, transplant, or mechanical circulatory support in any subgroup.
• Fewer reinterventions were observed in patients receiving methylprednisolone within STAT Category 1-3 operations, term infants, and those without CSD.
• No significant difference in hospital length of stay was found between groups.

Conclusions:

• Exploratory analyses suggest methylprednisolone is not associated with significant harm in infant heart surgery subgroups.
• Certain subpopulations, particularly those without chromosomal or syndromic diagnosis, may experience benefits from methylprednisolone regarding the composite outcome.
• Further underpowered studies indicate potential benefits in specific patient groups, warranting cautious consideration.